Confidence to achieve

Cutaquig® is indicated for replacement therapy in adults, children and adolescents (0–18 years) in:

Primary immunodeficiency (PID) syndromes with impaired antibody production.1

Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4g/l.1

Indications

Human normal Immunoglobulin

Cutaquig® is a 16.5% liquid preparation of highly purified human normal IgG, derived from large pools of human plasma. Human normal Immunoglobulin contains mainly IgG, with a broad spectrum of antibodies active against infectious agents.1

Learn more about Cutaquig®

Cutaquig® gives patients the flexibility to fit treatment around their individual lifestyle¹

Cutaquig® can be self-administered at home1

Cutaquig® can be administrated at flexible infusion regimens from daily up to every other week1

Discover resources to manage your patients' therapy

Dosing & Administration

Patients can have confidence in cutaquig®’s demonstrated efficacy1-6

Zero serious bacterial infections* in three clinical trials. One SBI not related to cutaquig® in the extension study1-6

Immunoglobulin replacement therapy has been demonstrated to reduce the frequency of severe infections and the use of antibiotics1-6

More about the efficacy of cutaquig

Cutaquig® is a high-quality SCIg product that is well tolerated, providing comfortable infusions for patients1-6

Cutaquig® has proven tolerability, with almost exclusively (>99%) mild or moderate infusion site reactions1-6

No serious systemic adverse drug reactions were reported in clinical trials1-6

More about Safety and Tolerability

References:

Cutaquig^® European Summary of Product Characteristics. November 2023.
Kobayashi, R.H., et al., Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (octanorm [cutaquig®]) in the treatment of patients with primary immunodeficiencies. Front Immunol, 2019. 10:40.
Kobayashi RH, et al. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig^®[octanorm]). Immunotherapy. 2021;13(10):813–24.
Kobayashi RH, et al. Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig^®) in the treatment of patients with primary immunodeficiencies. Clin Exp Immunol. 2022;210(2):91-103.
Latysheva E, et al. Efficacy and safety of octanorm (cutaquig^®) in adults with primary immunodeficiencies with predominant antibody deficiency: a prospective, open-label study. Immunotherapy. 2020;12(5):299–309.
Gupta S, et al. Subcutaneous Immunoglobulin 16.5% (Cutaquig^®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens. J Clin Immunol. 2023; 43(6):1414-1425.

This is an international website for cutaquig^® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).

If you wish to contact Octapharma please use the contact form on our corporate website www.octapharma.com.